Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957551 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
A Phase 1 study, sponsored by John Rieth.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03957551: Clinical Trial Phase 1 study, sponsored by John Rieth.
NCT03957551 is a Phase 1 study that was terminated before completion, run by John Rieth. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03957551, a Phase 1 study, was terminated before completion, sponsored by John Rieth.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
Primary Outcome
All adverse events (AEs) will be considered in DLT assessment unless an event is clearly unrelated to trial treatment. The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 will be used.
Interventions
- DRUG Pembrolizumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2025-10-17 |
| Phase | Phase 1 |
Why NCT03957551 stopped before completion
NCT03957551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03957551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03957551 about?
NCT03957551 is a clinical study titled "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma". The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
What is the current status of trial NCT03957551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-08-27. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT03957551?
The interventions under investigation include: Pembrolizumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03957551?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03957551's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI